Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
41.28 CHF | -2.19% | -5.50% | +16.86% |
Sales 2024 * | 182M 203M | Sales 2025 * | 206M 229M | Capitalization | 509M 568M |
---|---|---|---|---|---|
Net income 2024 * | 23M 25.64M | Net income 2025 * | 35M 39.01M | EV / Sales 2024 * | 3.12 x |
Net Debt 2024 * | 57.88M 64.51M | Net Debt 2025 * | 12.51M 13.94M | EV / Sales 2025 * | 2.54 x |
P/E ratio 2024 * |
21.2
x | P/E ratio 2025 * |
17.9
x | Employees | 147 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.61% |
Latest transcript on Basilea Pharmaceutica AG
1 day | -1.13% | ||
1 week | -4.47% | ||
Current month | -4.58% | ||
1 month | -2.91% | ||
3 months | +9.02% | ||
6 months | +15.35% | ||
Current year | +18.13% |
Managers | Title | Age | Since |
---|---|---|---|
David Veitch
CEO | Chief Executive Officer | 59 | 14-08-31 |
Adesh Kaul
DFI | Director of Finance/CFO | 50 | 08-12-31 |
Gerrit Hauck
CTO | Chief Tech/Sci/R&D Officer | 60 | 18-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nicole Onetto
BRD | Director/Board Member | 71 | 17-04-26 |
Leonard Kruimer
BRD | Director/Board Member | 66 | 21-12-31 |
Director/Board Member | 69 | 13-04-08 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 775 M€ | -.--% | - | |
0.00% | 10 M€ | -3.35% | - | |
0.00% | 32 M€ | +4.30% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-10 | 41.25 | -2.25% | 6 039 |
24-06-07 | 42.2 | +0.84% | 16,737 |
24-06-06 | 41.85 | -1.41% | 8,488 |
24-06-05 | 42.45 | +1.31% | 16,193 |
24-06-04 | 41.9 | -4.01% | 31,319 |
Delayed Quote Swiss Exchange, June 10, 2024 at 03:32 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.13% | 568M | |
+51.85% | 57.87B | |
+41.70% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- BSLN Stock